Navigation Links
Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
Date:9/12/2011

>www.savient.com.

FORWARD-LOOKING STATEMENTSAll statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the safety and efficacy of KRYSTEXXA®, status of our KRYSTEXXA marketing efforts and additional plans related thereto, market demand and reimbursement for KRYSTEXXA, our view of the refractory chronic gout (RCG) market size based on the completion of our recent comprehensive study, and our market expansion plans including our MAA filing before the EMA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, our ability to commercialize KRYSTEXXA; the risk that the market for KRYSTEXXA is smaller than we have anticipated; our ability to retain the personnel whom we have hired and to hire the remaining personnel necessary to complete the build out of our commercial team; our reliance on third parties to manufacture KRYSTEXXA; competition from existing therapies and therapies that are currently under development, includi
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
2. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
3. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
4. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
5. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
6. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
8. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
9. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
10. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has ... (London, UK - November 19-20, 2015)" conference to ... will cover industry case studies, regulatory updates, latest therapies ... Dr Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar ...
(Date:9/2/2015)... 2, 2015   Gulf Coast Tattoo Removal is the ... cutting-edge Astanza Duality laser in Southern Mississippi . ... tattoo regret and take back control of their skin. The clinic ... its services to Biloxi , Gulfport ... tattoo regret being as prevalent as it is, I was surprised ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ... "Medical Device Studies: Clinical Evidence (London, UK - ... This course has been designed ... clinical evidence required for medical devices and in-vitro ... medical devices and the emphasis on high quality, ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... EyeScience(TM) ( www.eyescience.com ) announced today that their ... and Dry Eye Formula(TM) are the only ocular ... their offices and through mass market retail. This announcement comes ... demand for the most complete eye vitamins available for AMD ...
... , KYOTO, Japan and PRINCETON, N.J., Nov. 11 ... NJ, USA) today announced that both parties have entered ... based on the Radiography System of Shimadzu featuring its ... applications. , This partnership contains ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3Shimadzu and EDDA Announce Business Partnership on X-ray Chest CAD Applications 2Shimadzu and EDDA Announce Business Partnership on X-ray Chest CAD Applications 3
(Date:9/2/2015)... ... September 02, 2015 , ... According to an article published August 12 by International ... aims to do away with grand juries in cases meant to decide if a police ... response to grand jury decisions in Ferguson and New York City that absolved police officers ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... – in the news recently following a decision by the Centers for Medicare ... is likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announced today the launch of its enhanced, cloud-based mobile ePrescribing application. The release ... focus on improving prescriber usability. A leader in health technology, RxNT was one ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... incoming goods, intermediate or final products. Automating sample handling makes density measurements more ... handling, showing each step of the automated workflow and the advantages compared to ...
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC and ... earned international recognition as a premier center for treatment of and research into ... internal bleeding and stroke. , Cure HHT, previously known as The HHT ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... on the development and commercialization of proprietary pharmaceuticals ... partners , today announced that under the Special ... with the United States Food and Drug Administration ... protocol for crofelemer for the treatment of chronic ...
... Functional foods could be the rage today in advanced ... better ask some tough questions before they decide ... ,Currently the international functional foods market is a ... ,* Margarines that lower bad cholesterol (LDL). ...
... at the University of Southern California have applied a ... clear up an old puzzle of the global carbon ... an advanced online publication of The ISME Journal. ... for nanometer-scale, secondary ion mass spectrometry) located at Lawrence ...
... to get hookah smoking exempted from Englands smoking ban ... the health effects , doctors writing in this weeks ... ,A hookah is a glass based waterpipe used ... for smoking herbal fruits after meals, but it is ...
... disease gives a more accurate measure of how many UK ... adults are most likely to benefit from treatment . ... the general population without pre-existing cardiovascular disease or diabetes, there ... Britain at high risk of developing heart disease. This is ...
... and Children's Hospital, Adelaide in Australia has raised serious questions ... are exposed to every day. ,Titled The ... ageing facilities in two of the hospital's oldest buildings and ... ,It states: "WCH is experiencing immediate facilities, infrastructure and related ...
Cached Medicine News:Health News:Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer 2Health News:Functional Food What is That, Ask First 2Health News:Functional Food What is That, Ask First 3Health News:Nanospectrometer Aids in Identifying Nutrient Cycle 2Health News:Ban on Hookah Smoking Should Stay, Argue Doctors 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 3Health News:Concerns Raised Over Risks for Patients and Staff in Australian Hospital 2
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: